As of fiscal year 2013 Yale research has had 1,815 awards totaling $510.4 million, 416 U.S. and 704 worldwide active patents for Yale inventions, and 58 Yale-founded biotech companies.
The School of Medicine has extraordinary strength in the basic sciences and consistently ranks in the top handful of medical schools receiving funding from the National Institutes of Health.
Toby C. Chai, MD
Darryl T. Martin, Ph.D.
Dr. Brian Shuch
Brian M. Shuch, MDis a graduate of the University of Michigan and received his MD from New York University before completing his urology residency and surgery internship at the University of California - Los Angeles (UCLA). During residency he completed an NIH/K30 fellowship program in Translational Investigation. He later completed a urologic three-year urologic oncology fellowship at the National Cancer Institute (NCI). He has had several years of kidney and prostate cancer laboratory research experience in the laboratories of Drs. Arie Belldegrun, Marston Linehan, Don Bottaro, Iman Osman, and Samir Taneja. Additionally he has received extensive clinical trial experience from his time at UCLA and the NCI.
Dr. Shuch's research interests involve both translational research and clinical trials. His research focus is the identification of genetic causes of kidney cancer, integrating genomic tools into the patient management, understanding the mechanisms of sarcomatoid transformation, and the development of new therapeutic strategies for high-risk patients. He is working closely with Drs. Harriet Kluger and Mario Sznol to expand the translational kidney cancer research efforts and the clinical trial portfolio at Yale.Since coming to New Haven, Dr. Shuch has helped established a biospecimen repository for the urologic oncology translational research. Additionally he has partnered with Dr. Allen Bale and Ellen Matloff in the Hereditary Cancer Program to form a multi-disciplinary program for Kidney Cancer Genetic Evaluation. This program provides comprehensive genetic evaluation for individuals with familial kidney cancer, early-disease onset, and bilateral/multifocal kidney cancer. Nationally, he is a member of SWOG, the Society of Urologic Oncology Clinical Trials Consortium- Renal Committee, and is a member of the working group for the Cancer Genome Atlas Chromophobe and Papillary Kidney Cancer groups.
Dr. Simon P. Kim
Dr. Kim cares for patients with bladder, kidney, and prostate cancer through the Prostate and Urologic Cancers Program at Smilow Cancer Hospital. His research focus is on health services research in improving the delivery of healthcare and outcomes for patients diagnosed with genitourinary malignancies. Dr. Kim is part of the Yale COPPER Program, under the direction of Drs. Cary Gross and Xiaomei Ma.